BIBF 1202 is primarily investigated for its potential therapeutic applications in the treatment of cancer. It functions as a triple angiokinase inhibitor, targeting key receptors involved in angiogenesis, such as VEGFR, FGFR, and PDGFR. By inhibiting these pathways, BIBF 1202 can disrupt the formation of new blood vessels that supply tumors, thereby limiting their growth and spread. This makes it a promising candidate for use in various solid tumors, including lung, ovarian, and colorectal cancers. Additionally, its mechanism of action is being explored in combination therapies to enhance the efficacy of existing treatments like chemotherapy or radiation. Research is ongoing to evaluate its safety, tolerability, and effectiveness in clinical trials.